Product & Industry News
Eric Rhodes headshot
ERS Genomics licenses CRISPR gene editing technology

ERS Genomics licenses CRISPR gene editing technology

ERS Genomics licenses CRISPR gene editing technology to Bioneer to further advance preclinical disease modelling.

ERS Genomics Limited and Bioneer A/S today announced the signing of a license agreement providing Bioneer access to CRISPR/Cas9 genome editing technology intellectual property. Bioneer, a Denmark based life science research and technology provider, will utilize CRISPR/Cas9 technology to generate a range of innovative human cell based disease models.

Under the terms of the license, Bioneer is able to generate and commercialize CRISPR-edited cell based models, broadening its core capabilities and expanding on Bioneer's expertise in biomedical research support.

Eric Rhodes, CEO of ERS Genomics, said: “Bioneer has proven expertise in a broad array of biomedical fields. Adding CRISPR/Cas9 to their toolbox ensures they remain on the leading edge of technology. We are very pleased that Bioneer chose to expand on its service offering by licensing CRISPR/Cas9 technology through ERS Genomics."

“This cutting-edge technology will complement Bioneer’s competences in advanced preclinical disease modelling.” stated Lars H. Pedersen, CEO of Bioneer. Christian Clausen, CSO of Bioneer continues: “Bioneer is working with both industry and academia to solve complex disease relevant questions by using advanced disease modelling. The CRISPR/Cas9 tools will enable clients and collaborators to precisely tailor their preclinical modelling strategies to their specific needs for predictive in vitro models. ”

Financial details of the agreement were not disclosed.